Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
The intervention group saw a minimal increase in utilization (1.36% to 1.45%) compared to the control group (4.11% to 6.80%), with corresponding containment of per-member-per-month costs (PMPM) (15% vs 79% increase)
This modification helps the molecule bind to albumin, a protein that circulates in the blood
Increasing awareness of diabetes and obesity, coupled with rising disposable incomes and government initiatives to improve chronic disease management, are key factors driving the significant growth potential of the GLP-1 receptor agonist market in the Asia Pacific region
Therefore, while supply of the medicine is expected to be limited for the foreseeable future, Novo Nordisk stated that a proportion of available supply will be allocated for use only within the NHS
The average follow-up time with participants was 39.8 months, and the average time participants took semaglutide was 34.2 months
US$ 22.96
US$ 25.12
US$ 22.55
US$ 22.31
US$ 22.56
US$ 22.67
US$ 21.50
US$ 28.94
